Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

OBE2109 suppressed estradiol levels to the target range and reduced endometriosis-related pelvic pain severity across the three Phase 2 clinical trials (no add back) KLH1202 TRIAL: % OF PATIENTS AT VARIOUS ESTRADIOL LEVELS IN KLH1202 TRIAL AT WEEK 12 KLH1202 TRIAL: AVERAGE CHANGE IN SEVERITY OF PELVIC PAIN OVER TIME (MENSTRUAL AND NON-MENSTRUAL PAIN    COMBINED) OBE2109 50 mg OBE2109 100 mg OBE2109 200 mg 0 Placebo Pain Pelvic of y -0.5 Severit *** e *** * *** * *** p < 0.05* ** Averag ** p < 0.01** Δ *** p < 0.001*** Two sample t -test ** vs Placebo -1 Pretreatment Week 4 Week 8 Week 12 Post-treatment    Time (Weeks) (Week 4)